Physician profile
Daniel Castro
NPI 1821002700
$1,599.96
in general payments reported to CMS, 2019-2025
23 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $58.77 · 2021: $268 · 2022: $472 · 2023: $278 · 2024: $204 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $329.92 | 2021-2025 | Rybelsus, Ozempic |
| Insulet Corporation | $212.57 | 2021-2023 | Omnipod |
| Corcept Therapeutics | $201.41 | 2021-2023 | Korlym |
| Dexcom, INC. | $147.19 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $98.41 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.59 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $72.36 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Medtronic, INC. | $67.12 | 2022-2025 | Intellis Adaptivestim |
| Amgen INC. | $45.54 | 2020 | |
| Sanofi-Aventis U.S. LLC | $39.01 | 2024 | |
| Xeris Pharmaceuticals, INC. | $36.62 | 2022-2023 | Gvoke Hypopen |
| Sequel Med Tech, LLC | $35.25 | 2025 | Twiist |
| Opko Pharmaceuticals, LLC | $31.43 | 2022 | |
| Beigene USA, INC. | $29.32 | 2022 | |
| Novartis Pharmaceuticals Corporation | $28.90 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $27.82 | 2024 | |
| Abbvie INC. | $24.24 | 2023 | Vraylar |
| Beta Bionics, INC. | $24.19 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Calliditas Therapeutics US INC. | $22.30 | 2025 | Tarpeyo |
| Amphastar Pharmaceuticals, INC. | $16.60 | 2025 | |
| Radius Health, INC. | $13.23 | 2020 | |
| Cequr Corporation | $11.64 | 2024 | Cequr Simplicity |
| Kerecis Limited | $10.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.